Results from commercial sales of predictive testing across the US and Australia have revealed the power of the geneType multi-risk test of Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) in identifying risk and improving the health of populations worldwide.
The non-invasive geneType multi-risk test is designed to uncover hidden risks of common yet serious diseases, identifying individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes.
GTG has tested a statistically significant number of people in Australia and the US since its geneType Risk Assessment Tests became available. Results of this testing reveal that 79.5% of people tested showed an elevated risk for at least one disease.
"Major step forward"
Identifying such elevated risks drives increased surveillance and screening which, ultimately, will lead to early detection, early intervention and can save lives.
“We have always believed the geneType multi-risk test is a major step forward in personalised medicine,” said geneType CEO Simon Morriss.
“These real-time results validate the utility of geneType in identifying people at high risk of disease, and importantly, they enable individuals and healthcare providers to take control of their health.”
Test, a “game-changer”
The implications of geneType’s multi-risk test are profound. With eight in 10 tested individuals discovering an elevated risk for serious diseases, there’s clearly a need for proactive health management.
This test not only identifies hidden risks but also initiates a shift towards a more preventative approach in healthcare, enhancing the chances of early intervention and treatment.
GTG outlined a number of reasons why its multi-risk test is a “game-changer” in preventive disease management:
- Comprehensive coverage - The multi-risk test evaluates genetic predispositions across a spectrum of serious diseases, covering 70% of annual mortality and morbidities — providing a clearer view of an individual’s health risks.
- Non-invasive procedure - The geneType test uses a simple, non-invasive saliva sample, making it accessible to a much wider population than a blood sample.
- Actionable outcomes - Each test in geneType’s portfolio comes with guideline-driven, actionable outcomes, empowering patients and healthcare providers to make informed decisions.
- Early detection saves lives - Identifying individuals at high risk enables proactive monitoring and preventative measures, significantly improving health outcomes.
- Personalised care - This test epitomises the power of genomics and personalised care, tailoring health management to the individual.